#	Pagina
attuale pagina	/open-h2020/projects/226396/index.html
-1	/open-consip/fornitori/2021/profilo-01164570358/index.html
-2	/open-consip/fornitori/2021/profilo-02097640342/index.html
-3	/open-h2020/projects/208694/index.html,www.fabiodisconzi.com/%7B-%7D/per-topic/group/221743/index.html
-4	/open-consip/fornitori/2021/profilo-01732500341/index.html
-5	/open-consip/fornitori/2015/profilo-04723770659/index.html
-6	/open-consip/fornitori/2019/profilo-02405600228/index.html
-7	/open-consip/fornitori/2019/profilo-00540980216/index.html
-8	/open-consip/fornitori/2014/profilo-03907580280/index.html
-9	/open-consip/fornitori/2014/profilo-10528261000/index.html
-10	/open-h2020/per-topic/merel/list/index.html

Opendata, web and dolomites

MEISi SIGNED

Druggable Small Molecule Inhibitor of MEIS Proteins

Total Cost €

EC-Contrib. €

Partnership

Views

MEISi project word cloud

Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.

share deep entry molecule deaths inhibitors customers segment 29 benchmarking diseases national cancer druggable deadliest never company prestigious pct indicate validated strategy cvds cell 44 tools strategies mechanisms innovative selective therapeutics meinox drug family patented countries pbx motivates ending plan ncds 71 protein significance tackling tgif2 2018 active competitive global nature market discovery globally diabetes ingredients meisi published commercialization substance stem co biology class modulate proper startup metabolism sizes oncology accounting channels plays small meis 10m markets critical proteins molecular performing pharmaceutically inhibits hoxa9 nearly tech conduct journals feasibility usd regulations pending owing massive 3b cardiovascular first efforts benefit noncommunicable risk

Project "MEISi" data sheet

The following table provides information about the project.

Coordinator	MEINOX ILAC TEKNOLOJILERI AS Organization address address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19 city: SARIYER ISTANBUL postcode: 34467 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Turkey [TR]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-12-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MEINOX ILAC TEKNOLOJILERI AS MEINOX ILAC TEKNOLOJILERI AS Organization address address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19 city: SARIYER ISTANBUL postcode: 34467 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	TR (SARIYER ISTANBUL)	coordinator	50˙000.00

Map

Project objective

MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.

MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.

Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.

Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.